{{org_field_logo}}

{{org_field_name}}

Registration Number: {{org_field_registration_no}}


Safe Management of Warfarin and Anticoagulant Therapy Policy

1. Purpose

The purpose of this policy is to ensure that {{org_field_name}} maintains a safe, effective, and compliant approach to managing warfarin and other anticoagulant therapies for service users receiving domiciliary care. Anticoagulant medications, including warfarin, rivaroxaban, apixaban, dabigatran, and edoxaban, are high-risk medicines that require careful monitoring, administration, and documentation to prevent serious complications such as excessive bleeding or clot formation.

This policy supports compliance with the Regulation and Inspection of Social Care (Wales) Act 2016, the Regulated Services (Service Providers and Responsible Individuals) (Wales) Regulations 2017, as amended, including Regulations 12, 15, 21, 34, 36 and 58, and the associated Welsh Government statutory guidance. For adults receiving domiciliary support, the policy also has regard to NICE Guideline NG67, Managing medicines for adults receiving social care in the community, and NICE Quality Standard QS171, Medicines management for people receiving social care in the community. The service must provide anticoagulant support in accordance with the individual’s current prescription, personal plan, medicines-support assessment and instructions issued by the prescribing or anticoagulation service.

Where the person receiving care is under 18 years of age, anticoagulant support must be provided strictly in accordance with the child’s individual health plan, prescription, personal plan and written instructions from the responsible paediatric, haematology or anticoagulation team. Adult anticoagulation guidance must not be applied to a child unless the responsible prescribing clinician has confirmed that it is appropriate.

2. Scope

This policy applies to:

3. Understanding Anticoagulant Therapy Risks

Anticoagulant medications prevent blood clot formation but pose risks if not managed properly. Common risks include:

To ensure safe and effective care, {{org_field_name}} follows a structured approach to monitoring, administration, and documentation.

3.1 Distinction Between Warfarin and Direct-Acting Oral Anticoagulants

Warfarin and direct-acting oral anticoagulants must not be managed as though they have identical monitoring and dosing requirements.

4. Roles and Responsibilities

4.1 Responsibilities of Care Staff

Care staff must not make any decisions regarding warfarin dosages but are responsible for:

4.2 Responsibilities of the Registered Manager

The Registered Manager must ensure that:

4.3 Responsibilities of Healthcare Professionals

5. Assessment, Consent, Capacity and Level of Medicines Support

5.1 Medicines-Support Assessment

Before staff provide any support with an anticoagulant, the service must assess and record:

5.2 Consent and Mental Capacity

Staff must obtain the person’s valid consent before providing medicines support. Consent and the agreed level of support must be recorded in the personal plan.

Where there is reason to doubt the person’s capacity to make a particular decision about their anticoagulant treatment or medicines support, staff must follow the Mental Capacity Act 2005. Capacity must be considered in relation to the specific decision and at the time the decision is required. Any best-interests decision must be made and recorded in accordance with the Act and must involve relevant persons and professionals.

Staff must not administer an anticoagulant covertly unless a lawful, person-specific best-interests process has been completed, the prescriber and pharmacist have provided appropriate written instructions and the decision is documented and regularly reviewed.

5.3 Self-Administration

The person must be supported to manage their own anticoagulant wherever this is safe and consistent with their wishes and assessed needs. Any decision for staff to take over part or all of the person’s medicines management must be proportionate, agreed and recorded. The arrangements must be reviewed following any change in the person’s health, cognition, treatment, ability or wishes.

6. Safe Administration of Warfarin and Anticoagulant Therapy

6.1 Warfarin Dosage Instructions and INR Monitoring

Warfarin must be administered only where the service holds a current, legible and authorised written dosage instruction. The instruction may be contained in an anticoagulation record, written dosing schedule, prescription or other authorised record accepted under the organisation’s medicines procedure.

Staff must:

Care staff must not interpret an INR result, calculate a dose or amend the dosage schedule. A result must be reviewed and converted into a clear dosage instruction by the authorised prescriber or anticoagulation service.

Direct-acting oral anticoagulants must be administered according to their current prescription and do not require routine INR monitoring.

6.2 Medication Administration Guidelines

6.3 Storage and Handling of Anticoagulants

In a domiciliary support service, medicines normally remain the property and responsibility of the individual. Storage arrangements must promote independence while managing any assessed risk.

7. Recognising and Responding to Side Effects and Emergencies

7.1 Signs of Excessive Anticoagulation (Bleeding Risks)

Care staff must immediately report and escalate if a service user experiences:

Staff must treat severe, uncontrolled or unexplained bleeding, vomiting or coughing blood, suspected internal bleeding, sudden severe headache, collapse, marked confusion, breathing difficulty, or any significant head injury as a medical emergency and call 999.

Any fall, blow to the head or suspected head injury involving a person taking an anticoagulant must be escalated promptly for clinical assessment, even where there is no obvious external bleeding. Staff must follow NHS 111 Wales, emergency-service or prescriber advice and must not rely solely on visible symptoms.

Less severe bleeding, repeated minor bleeding, unexplained bruising or a significant change in the person’s condition must be reported promptly to the manager and referred for clinical advice in accordance with the personal plan.

6.2 Signs of Inadequate Anticoagulation (Clotting Risks)

Emergency medical attention is required if a service user experiences:

If any of these symptoms occur, staff must call 999 immediately, provide first aid within their competence, remain with the person where it is safe to do so, make the person’s medicines information available to the emergency service and notify the Registered Manager. The GP or specialist team must be informed after urgent emergency action has been initiated, where appropriate.

8. Dietary and Drug Interactions

8.1 Food, Alcohol and Dietary Considerations

Dietary advice must be individualised and must not be used by care staff to change, restrict or stop a person’s normal diet without advice from an appropriate healthcare professional.

8.2 Prescribed, Non-Prescribed and Complementary Medicines

Anticoagulants can interact with prescribed medicines, over-the-counter medicines, herbal products and supplements. Staff must:

Staff must not administer aspirin, ibuprofen or another non-steroidal anti-inflammatory medicine unless it has been prescribed or otherwise clinically authorised for that person and is included in the medicines administration arrangements. Paracetamol must also be used only in accordance with its authorised directions because regular or excessive use may require clinical review in a person taking warfarin.

9. Training, Competence and Delegated Tasks

Staff must not administer or provide assessed assistance with an anticoagulant until they have:

Competence must be documented and reassessed:

Where a healthcare professional delegates a healthcare activity associated with anticoagulant treatment, the service must obtain and retain clear written information covering:

The provider must not accept a delegated activity unless it can demonstrate that appropriately trained, competent and supervised staff are available and that the activity is consistent with the service’s statement of purpose and insurance arrangements.

10. Documentation and Audit Procedures

To ensure compliance and best practice, {{org_field_name}} implements:

11. Communication, Transfers and Changes to Treatment

The service must maintain clear arrangements for communication between the individual, their representative where appropriate, care staff, the prescriber, supplying pharmacy, anticoagulation service, community nursing service and commissioner.

When anticoagulant treatment is started, stopped, withheld or changed, the manager or authorised person must ensure that:

Following discharge from hospital, transfer between services or a change of care provider, staff must not assume that the previous anticoagulant dose remains current. Medicines must be reconciled against the discharge information, dispensing label and current authorised instructions, and any discrepancy must be resolved before staff administer the medicine.

12. Related Policies

This policy should be read alongside:

13. Policy Review

This policy will be reviewed annually or sooner if legislation, CIW guidelines, or best practices change. The policy must be reviewed at least annually and sooner following a relevant legislative or national-guidance change, a significant anticoagulant-related incident, an identified medicines-management trend, a safeguarding concern, a recommendation from CIW or another relevant authority, or a material change in service delivery. Changes must be communicated to affected staff and incorporated into training, competency assessment, personal-plan documentation and audit arrangements as appropriate. Information directly affecting an individual’s care must be communicated to the individual and their representative, where lawful and appropriate, in an accessible format.


Responsible Person: {{org_field_registered_manager_first_name}} {{org_field_registered_manager_last_name}}
Reviewed on:
{{last_update_date}}
Next Review Date:
{{next_review_date}}
Copyright © {{current_year}} – {{org_field_name}}. All rights reserved.

Leave a Reply

Your email address will not be published. Required fields are marked *